Estoraque

Estoraque (Myrica pubescens) contains terpenoids including myricanol and myricanone, alongside flavonoids such as myricetin and myricitrin, which exert antioxidant effects through free radical scavenging and anti-inflammatory activity through inhibition of pro-inflammatory mediators. In vitro studies using methanol extracts demonstrated inhibition of HepG2, HeLa, and MDA-MB-231 cancer cell lines at approximately 46–50% at a concentration of 5 mg/ml, though no human clinical trial data currently validate these effects.

Origin & History

Myrica pubescens is native to the Andean regions of South America, particularly Bolivia, Peru, Ecuador, and Colombia, where it grows in montane cloud forests and highland scrublands at elevations between 1,500 and 3,500 meters. The plant is a shrub or small tree thriving in humid, well-drained soils characteristic of subtropical mountain environments. It has been used for generations by Andean and Bolivian indigenous communities, who harvest the resinous bark and leaves for medicinal preparations, though it is not formally cultivated on a commercial scale.

Historical & Cultural Context

Estoraque has been a component of traditional Andean and Bolivian ethnomedicine for centuries, with indigenous communities of the Bolivian highlands and Peruvian Andes incorporating the resinous bark into respiratory therapies, particularly for coughs, bronchitis, and altitude-related breathing difficulties. The aromatic resin, rich in volatile terpenoids, was historically burned as an incense-like fumigant in healing rituals and used practically to clear airways, a practice echoing the use of other Myrica species in Asian and North American indigenous traditions. In broader South American folk medicine, the plant has been used to treat skin inflammations, wounds, and gastrointestinal complaints, with bark decoctions considered a general-purpose tonic. The name 'Estoraque' is also used colloquially in parts of Latin America for other resin-producing plants (notably Liquidambar styraciflua), reflecting a shared cultural framework in which aromatic resins are valued as medicinal and spiritual substances.

Health Benefits

- **Respiratory Support**: The aromatic resin of Myrica pubescens has been traditionally inhaled or applied as a decoction in Bolivian medicine to ease bronchial congestion and respiratory inflammation, with terpenoid compounds hypothesized to exert mucolytic and anti-inflammatory effects on airway mucosa.
- **Antioxidant Activity**: Phenolic compounds including gallic acid (up to 5.03 mg/100 g fresh weight) and chlorogenic acid (up to 5.68 mg/g fresh weight) scavenge DPPH free radicals, chelate Fe²⁺ ions, and inhibit lipid peroxidation in vitro, indicating meaningful antioxidant capacity.
- **Anti-Inflammatory Effects**: Flavonoids such as myricetin and myricitrin found in bark and leaves suppress pro-inflammatory pathways in rodent models, though the precise molecular targets—such as COX or NF-κB inhibition—have not been formally characterized for this species.
- **Antimicrobial Properties**: Bark and leaf extracts have demonstrated antimicrobial activity against common bacterial and fungal pathogens in ethnomedicinal traditions, attributed to the combined action of terpenoids, gallic acid, and flavonoid glycosides disrupting microbial cell membranes.
- **Antihypertensive Potential**: Corchoionoside C and (6S,9R)-roseoside isolated from related Myrica species inhibit angiotensin-converting enzyme (ACE) at rates of 29.97% and 25.63% respectively at 100 μM in vitro, suggesting a mechanism relevant to blood pressure regulation.
- **Antidiabetic Activity**: Ethnomedicinal use for blood sugar regulation in Andean communities is partially supported by rodent model studies showing hypoglycemic effects, tentatively linked to polyphenol-mediated inhibition of carbohydrate-digesting enzymes such as α-glucosidase.
- **Cytotoxic and Anticancer Potential**: Methanol fruit extracts inhibited proliferation of HepG2 liver cancer (50%), HeLa cervical cancer (48.29%), and MDA-MB-231 breast cancer (46.19%) cell lines at 5 mg/ml via MTT assay, with activity attributed primarily to ferulic acid and gallic acid content.

How It Works

The primary antioxidant mechanism involves polyphenols—particularly gallic acid, chlorogenic acid, catechin, and the flavonoid myricetin—donating hydrogen atoms to neutralize DPPH and hydroxyl radicals, chelating pro-oxidant Fe²⁺ ions, and interrupting lipid peroxidation chain reactions in cellular membranes. The terpenoids myricanol and myricanone, along with the ionone glycosides corchoionoside C and roseoside, appear to modulate enzymatic activity, with corchoionoside C demonstrating ACE inhibition at 29.97% inhibition at 100 μM, likely through competitive or non-competitive binding at the enzyme's active site. Anti-inflammatory effects are attributed to flavonoid compounds interfering with arachidonic acid cascade enzymes and potentially downregulating NF-κB-mediated transcription of pro-inflammatory cytokines, though specific receptor binding or gene expression data for M. pubescens are not yet published. Anticancer cytotoxicity is tentatively linked to phenolic induction of apoptotic pathways in cancer cell lines, though the upstream targets—whether mitochondrial, caspase-mediated, or receptor-driven—have not been elucidated for this species.

Scientific Research

The scientific evidence base for Myrica pubescens (Estoraque) is limited to in vitro assays and animal model studies, with no published human clinical trials identified in the available literature as of 2024. The most detailed phytochemical and bioactivity data derive from studies on the closely related Myrica esculenta, which shares overlapping compound profiles including myricanol, myricetin, gallic acid, and chlorogenic acid, and these findings are cautiously extrapolated to M. pubescens. In vitro MTT cytotoxicity assays at 5 mg/ml show moderate cancer cell inhibition (46–50% across three cell lines), and ACE inhibition assays at 100 μM show modest enzyme suppression by select compounds, but these concentrations have not been translated into bioavailable human doses. Rodent studies support analgesic, antidiabetic, and anti-inflammatory activity but lack standardized dosing, pharmacokinetic characterization, or controlled methodology sufficient to draw clinical conclusions.

Clinical Summary

No human clinical trials have been conducted specifically on Myrica pubescens or its standardized extracts for any indication, including its primary traditional use in respiratory conditions. The existing evidence is restricted to in vitro cell-based assays and uncontrolled rodent experiments, which demonstrate biological plausibility for antioxidant, anti-inflammatory, antihypertensive, and anticancer activities but cannot establish efficacy, safe dosing, or clinical effect sizes in humans. Outcomes such as cancer cell inhibition (46–50% at 5 mg/ml) and ACE inhibition (~30% at 100 μM) are pharmacologically interesting but represent bench-level findings far removed from clinical applicability. Confidence in any therapeutic recommendation is very low, and use should be considered traditional and exploratory until properly designed clinical trials are completed.

Nutritional Profile

The fruits of Myrica pubescens contain total phenolics of 1.78–2.51 mg gallic acid equivalents per gram fresh weight and total flavonoids of 1.31–1.59 mg quercetin equivalents per gram fresh weight, indicating moderate polyphenol density comparable to other wild Andean berries. Specific quantified phytochemicals in fruits include chlorogenic acid (up to 5.68 mg/g fresh weight), gallic acid (5.03 mg/100 g fresh weight), and catechin (2.72 mg/100 g fresh weight). Bark and leaves contain the triterpenoids myricanol and myricanone, flavonoid glycosides myricetin-3-O-rhamnosides, sterols β-sitosterol and stigmasterol, and the ionone glycosides corchoionoside C and roseoside, though precise quantitative concentrations for these constituents have not been reported in published literature. Macronutrient and micronutrient profiles (protein, fat, carbohydrate, vitamins, minerals) have not been characterized for this species; bioavailability of phenolic compounds is expected to be influenced by the food matrix, gut microbiota metabolism, and the glycosylation state of flavonoid glycosides.

Preparation & Dosage

- **Traditional Bark Decoction (Respiratory Use)**: Bolivian and Andean herbalists prepare decoctions by simmering 5–10 g of dried bark in 250–500 ml of water for 15–20 minutes; ingested or used as steam inhalation for respiratory complaints; no validated dose.
- **Resin Inhalation**: The aromatic resin is traditionally burned or heated to release terpene-rich vapors for bronchial congestion relief; preparation is artisanal and non-standardized.
- **Aqueous Leaf Extract**: Leaves are steeped as a tea for anti-inflammatory and digestive applications; typical folk preparation uses 3–5 g dried leaf per cup of boiling water, steeped 10 minutes.
- **Methanol/Ethanol Extract (Research Grade)**: Used experimentally at 5 mg/ml in in vitro assays; no equivalent human supplemental dose has been established or validated.
- **Standardized Supplement Forms**: No commercially standardized capsule, tablet, or tincture forms with defined phytochemical content are currently available on the market.
- **Timing Notes**: Traditional preparations are typically consumed two to three times daily during acute respiratory illness; no pharmacokinetic data exist to guide optimal timing or duration of use.

Synergy & Pairings

In traditional Andean respiratory preparations, Estoraque resin is frequently combined with muña (Minthostachys mollis) and eucalyptus leaves, with the volatile terpene fractions of all three plants theoretically acting additively to promote bronchodilation and mucociliary clearance. Given its ACE-inhibitory phenolic content, Myrica pubescens may exhibit additive cardiovascular effects when combined with other polyphenol-rich botanicals such as hibiscus (Hibiscus sabdariffa), though this combination has not been formally studied. The antioxidant phenolics—particularly gallic acid and myricetin—may have enhanced bioavailability when co-administered with vitamin C or black pepper piperine, which are known to improve polyphenol absorption and reduce oxidative degradation of flavonoids in the gut.

Safety & Interactions

No formal human safety studies, toxicology reports, or controlled adverse event data have been published for Myrica pubescens or Estoraque resin preparations, making it impossible to establish a maximum safe dose or confirmed side effect profile. In vitro cytotoxicity data showing ~46–50% cancer cell inhibition at 5 mg/ml raise theoretical concerns about cytotoxic potential at high concentrations, but the relevance to oral human exposures at traditional doses is entirely unknown. Drug interactions have not been studied; however, given the ACE-inhibitory activity of isolated compounds (corchoionoside C, roseoside), caution is theoretically warranted in patients taking antihypertensive medications such as ACE inhibitors or ARBs, and the antidiabetic activity in rodent models suggests a potential additive hypoglycemic risk with insulin or oral antidiabetic drugs. Use during pregnancy and lactation is not recommended due to the complete absence of safety data; individuals with known allergies to Myricaceae family plants should also exercise caution.